Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action

Journal of Pharmacology and Experimental Therapeutics

Volumn 299, Issue 3, 2001, Pages 1140-1147

  Hassan, Saadia B ^a   Jonsson, Elin ^a   Larsson, Rolf ^a   Karlsson, Mats O ^b  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; GUANIDINE DERIVATIVE; N [6 (4 CHLOROPHENOXY)HEXYL] N' CYANO N'' (4 PYRIDYL)GUANIDINE; PACLITAXEL; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; CELL DEATH; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INCUBATION TIME; MODEL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL DIVISION; CYANIDES; ETOPOSIDE; GUANIDINES; HUMANS; PACLITAXEL; TIME FACTORS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0035192899     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. A phase I safety study of CHS 828 in patients with solid tumour malignancy
2. Molecular effects of paclitaxel: Myths and reality
3. Guanidino-containing drugs in cancer chemotherapy: Biochemical and clinical pharmacology
4. A mechanistic, predictive model of dose-response curves for cell cycle phase-specific and -nonspecific drugs
5. Antitumor properties of podophyllotoxin and related compounds
6. CHS 828, a novel pyridyl cyanoguanidine with potent antitumor activity in vitro and in vivo
7. NF-κB activation by camptothecin. A linkage between nuclear DNA damage and cytoplasmic signaling events
8. Schedule-dependent topoisomerase II-inhibiting drugs
9. Determination of drug effect on tumour cells, host animal toxicity and drug pharmacokinetics in a hollow-fibre model in rats
10. In vivo activity of CHS 828 on hollow-fibre cultures of primary human tumour cells from patients
11. Xpose - An S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM
12. Design and analysis of in vitro antitumor pharmacodynamic studies
13. A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression
14. The influence of the shape of the plasma drug concentration profile upon the pharmacological effect
15. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA)
16. Modeling of the time-dependency of in vitro drug cytotoxicity and resistance
17. 3-Aninobenzamide inhibits cytotoxicity induced by the novel antitumoural cyanoguanidine CHS 828
18. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia
19. Topotecan: What dose, what schedule, what route?
20. Kinetic analysis of cell killing effect induced by cytosine arabinoside and cisplatin in relation to cell cycle phase specificity in human colon cancer and Chinese hamster cells
21. An EORTC/ECSG phase I study of CHS 828, a cyanoguanidine in patients with refractory solid tumors
22. The taxanes: Dosing and scheduling considerations